As of May 29, 2025, Meridian Bioscience Inc (VIVO) reports a ROA (Return on Assets) of 9.17%.
ROA (Return on Assets) evaluates how effectively a company turns its assets into profits, showcasing resource utilization.
Historical Trend of Meridian Bioscience Inc's ROA (Return on Assets)
Over recent years, Meridian Bioscience Inc's ROA (Return on Assets) has shown significant volatility. The table below summarizes the historical values:
| Date | ROA (Return on Assets) |
|---|---|
| 2022-09-30 | 9.17% |
| 2021-09-30 | 15.88% |
| 2020-09-30 | 11.40% |
| 2019-09-30 | 7.50% |
| 2018-09-30 | 9.47% |
This slight downward trend highlights how Meridian Bioscience Inc manages its efficiency in using assets to generate earnings over time.
Comparing Meridian Bioscience Inc's ROA (Return on Assets) to Peers
To better understand Meridian Bioscience Inc's position, it's useful to compare its ROA (Return on Assets) against industry peers. Below are selected comparisons:
| Company | ROA (Return on Assets) |
|---|---|
| Meridian Bioscience Inc (VIVO) | 9.17% |
| Antares Pharma Inc (ATRS) | 17.98% |
| Lantheus Holdings Inc (LNTH) | 15.78% |
| West Pharmaceutical Services Inc (WST) | 13.52% |
| Utah Medical Products Inc (UTMD) | 11.32% |
| Atrion Corp (ATRI) | 7.44% |
Compared to its competitors, Meridian Bioscience Inc's ROA (Return on Assets) is among the highest compared to peers, demonstrating superior efficiency in generating earnings from assets.